For the first time, traditional drug spending has exceeded specialty drug spending, largely due to the demand for GLP-1s, according to a new report from Evernorth Research Institute. Evernorth ...

Drug discovery is a high-risk, high-cost endeavor, with over 90% of candidates failing in clinical development. A significant proportion of these failures stem from unresolved biopharmaceutic ...

Washington — President Trump signed an executive order on Thursday to reschedule marijuana to a lower drug classification, one of the most significant changes to drug policy in decades. "Today I'm ...

The U.S. Food and Drug Administration is actively steering drug developers away from traditional animal studies and toward ...